P22 Phage Shows Promising Antibacterial Activity under Pathophysiological Conditions
Authors:
Open Access
- 10 February 2022
- journal article
- research article
- Published by Fortune Journals in Archives of Microbiology & Immunology
- Vol. 06 (01) , 81-100
Abstract
The prevalence of multidrug resistant bacterial diseases is a major global health risk. Multidrug resistant bacterial diseases are prevalent, and the need for novel methods of treatment is essential to the preservation of public health. Annually foodborne pathogens cause 1.35 million infections and 26,500 hospitalizations in the United States alone. Foodborne pathogens such as Salmonella spp. are a major threat to public health. Bacteriophages offer a unique method for the treatment of these multidrug resistant bacteria. We studied the infection dynamics of a potential mono-phage therapy of Salmonella typhimurium under various pathophysiological conditions. Furthermore, we determined the resistance dynamics of Salmonella typhimurium against P22 phage treatment. We also determined synergy with antibiotics such as ampicillin and kanamycin. This research helps to further define and show the versatility of bacteriophages as potential novel treatment methods.Keywords
All Related Versions
This publication has 58 references indexed in Scilit:
- Co-Therapy Using Lytic Bacteriophage and Linezolid: Effective Treatment in Eliminating Methicillin Resistant Staphylococcus aureus (MRSA) from Diabetic Foot InfectionsPLOS ONE, 2013
- Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestisBiochemical Society Transactions, 2012
- Salmonella entericaserovars Typhimurium and Typhi as model organismsVirulence, 2012
- Structural engineering of a phage lysin that targets Gram-negative pathogensProceedings of the National Academy of Sciences, 2012
- Phages in natureBacteriophage, 2011
- Orally Administered P22 Phage Tailspike Protein Reduces Salmonella Colonization in Chickens: Prospects of a Novel Therapy against Bacterial InfectionsPLOS ONE, 2010
- Bacteriophage Host Range and Bacterial Resistance2010
- Has the era of untreatable infections arrived?Journal of Antimicrobial Chemotherapy, 2009
- Bacteriophage genomicsCurrent Opinion in Microbiology, 2008
- Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage GrowthPLOS ONE, 2007